Simulations Plus, Univ. of Pittsburgh partner to evaluate large-molecule drugs

By The Science Advisory Board staff writers

February 23, 2021 -- Medical simulation software company Simulations Plus and the University of Pittsburgh Drug Discovery Institute (UPDDI) have jointly received a phase I grant from the U.S. National Institutes of Health (NIH)-funded Small Business Innovation Research (SBIR) grant to support their large-molecule safety collaboration.

As a result of the funding from the NIH, Simulation Plus' Dilisym Services (DSS) division will combine its software with UPDDI's biomimetic human liver microphysiological systems (vLAMPS) experimental liver model and the microphysiology systems database to predict the safety of large molecules such as proteins for treating diseases.

In the first phase of the project, a beta version of software will be constructed and vLAMPS testing will be performed for several large molecules captured in the database. If the objectives are successfully completed, Simulation Plus and UPDDI will then apply for a larger phase II grant to fully fund development of a joint commercial offering, they said.

Proteomics helps researchers pick the best anti-SARS-CoV-2 nanobodies
A new high-throughput proteomics-based strategy to identify tiny antibody fragments -- called nanobodies -- may provide an efficient and effective method...
Novel microscopy method unlocks clues to nanomedicine interactions
A new mixed microscopy method has led to a better understanding of the interactions of proteins in the body with nanoparticles used for biotherapeutic...
Deep-learning approach easily identifies druggable protein sites
A deep-learning algorithm was able to automatically identify binding sites on proteins that could be good targets for drug candidates, according to research...
SARS-CoV-2 spike protein hinges like leg joints to seek receptors
New research demonstrates that the SARS-CoV-2 spike protein may be more flexible than previously thought, with hinges similar to leg joints to seek receptors...
Simulations Plus debuts COVID-19 consulting program
Medical simulation software company Simulations Plus announced that it has created a program to speed up consulting assistance to scientists working on...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter